ikt-148009 as a potential disease-modifying therapy in parkinson's disease
Published 1 year ago • 1.5K plays • Length 3:56Download video MP4
Download video MP3
Similar videos
-
4:55
parkinson's disease modification through c-abl inhibition
-
3:40
upcoming studies on ikt-148009 in msa
-
1:31
the challenges in disease-modifying therapy development in parkinson’s disease
-
4:47
update on disease-modifying therapies in parkinson’s disease
-
2:12
key clinical trials of disease modifying therapies in parkinson's disease
-
1:19
ikt-148009 - addressing loss of function in parkinson's patients
-
2:22
enrolling treatment-naive patients in parkinson’s disease clinical trials
-
2:43
update on parkinson’s disease clinical trials
-
8:59
phase ii trial of ambroxol as a disease modifying therapy for parkinson’s disease dementia
-
1:44
exploratory delayed-start analysis of pasadena in early-stage parkinson's disease
-
1:21
investigating α-synuclein aggregation as a therapeutic target in parkinson’s disease
-
4:31
is α-synuclein a useful therapeutic target in parkinson's disease?
-
59:56
inhibikase 2023 virtual r&d event
-
9:49
inhibikase therapeutics talks focus on developing therapeutics for parkinson's and related disorders
-
4:00
peripheral α-synuclein as a parkinson’s disease biomarker
-
2:05
alpha-synuclein inhibitors, kinase inhibitors & targeting mitochondria in parkinson’s disease
-
2:17
analysis of the therapeutic potential of c-abl inhibition in parkinson's disease & msa
-
2:26
alpha-synuclein as a therapeutic target for parkinson's disease
-
3:30
advancements in cell therapies for parkinson’s disease